POLE and colorectal carcinoma: Our neoadjuvant sintilimab combination regimen in patients with cT4NxM0 pMMR/MSS CRC was associated with fewer severe adverse events and no delay in planned surgery, leading to a pCR rate of 54.5% (12/22 patients) and an MPR rate of 81.8% (18/22 patients) in resected tumors, including in two POLE‐mutated patients.